{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:13:21Z","timestamp":1761174801220,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ejogrb.2021.07.035","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T05:18:14Z","timestamp":1627103894000},"page":"266-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The impact of indomethacin on the number of oocytes retrieved and IVF outcomes in patients with poor ovarian response"],"prefix":"10.1016","volume":"264","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4191-4004","authenticated-orcid":false,"given":"Adem","family":"Yavuz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokalp","family":"Oner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Tas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Sonmezer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejogrb.2021.07.035_b0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.rbmo.2015.03.002","article-title":"How to define, diagnose and treat poor responders? Responses from a worldwide survey of IVF clinics","volume":"30","author":"Patrizio","year":"2015","journal-title":"Reproductive BioMedicine Online"},{"issue":"2","key":"10.1016\/j.ejogrb.2021.07.035_b0010","doi-asserted-by":"crossref","first-page":"e039122","DOI":"10.1136\/bmjopen-2020-039122","article-title":"Controlled ovarian hyperstimulation for poor ovarian responders undergoing in vitro fertilisation\/intracytoplasmic sperm injection: a protocol for systematic review and Bayesian network meta-analysis","volume":"11","author":"Yang","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejogrb.2021.07.035_b0015","first-page":"4:CD001750","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","author":"Al-Inany","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ejogrb.2021.07.035_b0020","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1210\/jcem-67-3-524","article-title":"Evidence of differential control of FSH and LH secretion by gonadotropinreleasing hormone (GnRH) from the use of a GnRH antagonist","volume":"67","author":"HALL","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2021.07.035_b0025","first-page":"556","article-title":"Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols","volume":"32","author":"Toftager","year":"2017","journal-title":"Hum Reprod"},{"issue":"6","key":"10.1016\/j.ejogrb.2021.07.035_b0030","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/humrep\/den107","article-title":"Flexible GnRH antagonist versus flare-up GnRH agonist protocol in poor responders treated by IVF: a randomized controlled trial","volume":"23","author":"Lainas","year":"2008","journal-title":"Hum Reprod"},{"issue":"1","key":"10.1016\/j.ejogrb.2021.07.035_b0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1477-7827-10-26","article-title":"GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF\/ET)","volume":"10","author":"Depalo","year":"2012","journal-title":"Reprod Biol Endocrinol"},{"issue":"1","key":"10.1016\/j.ejogrb.2021.07.035_b0040","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.fertnstert.2014.04.010","article-title":"Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surge in vitro fetilizzayion cycles","volume":"102","author":"Reichman","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2021.07.035_b0045","doi-asserted-by":"crossref","unstructured":"Chen Q, Chai W, Wang Y, Cai R, Zhang S, et al. Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing in vitro Fertilization Treatment: A Randomized Controlled Trial. Frontiers in Endocrinology 2019;10:796.","DOI":"10.3389\/fendo.2019.00796"},{"issue":"11","key":"10.1016\/j.ejogrb.2021.07.035_b0050","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1093\/humrep\/17.11.2825","article-title":"Follicular administration of a cyclooxygenase inhibitor can prevent oocyte release without alteration of normal luteal function in rhesus monkeys","volume":"17","author":"Duffy","year":"2002","journal-title":"Hum Reprod"},{"issue":"3","key":"10.1016\/j.ejogrb.2021.07.035_b0055","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0015-0282(16)58153-9","article-title":"Effects of indomethacin on follicular structure, vascularity, and function over the periovulatory period in women","volume":"65","author":"Athanasiou","year":"1996","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.ejogrb.2021.07.035_b0060","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/humrep\/dep424","article-title":"Oral administration of the cyclooxygenase-2 (COX-2)- inhibitor meloxicam blocks ovulation in non-human primates when administered to simulate emergency contraception","volume":"25","author":"Hester","year":"2010","journal-title":"Hum Reprod"},{"issue":"3","key":"10.1016\/j.ejogrb.2021.07.035_b0065","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.rbmo.2011.12.002","article-title":"Short-term, low-dose, non-steroidal anti-inflammatory drug application diminishes premature ovulation in natural-cycle IVF","volume":"24","author":"Kawachiya","year":"2012","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"10.1016\/j.ejogrb.2021.07.035_b0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1472-6483(10)60581-0","article-title":"Spontaneous ovulation rate before oocyte retrieval in modified natural cycle IVF with and without indomethacin","volume":"16","author":"Kadoch","year":"2008","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"10.1016\/j.ejogrb.2021.07.035_b0075","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.rbmo.2013.05.009","article-title":"Effectiveness of indometacin to prevent ovulation in modified natural-cycle IVF: a randomized controlled trial","volume":"27","author":"Rijken-Zijlstra","year":"2013","journal-title":"Reprod Biomed Online"},{"issue":"7","key":"10.1016\/j.ejogrb.2021.07.035_b0080","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/humrep\/der092","article-title":"ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: The Bologna criteria","volume":"26","author":"Ferraretti","year":"2011","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.ejogrb.2021.07.035_b0085","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/humrep\/dep392","article-title":"Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception","volume":"25","author":"Jesam","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2021.07.035_b0090","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/0091270006289483","article-title":"Delay of ovulation by meloxicam in healthy cycling volunteers: a placebo controlled, double blind, crossover study","volume":"46","author":"Bata","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ejogrb.2021.07.035_b0095","doi-asserted-by":"crossref","unstructured":"Y.-G. Wu D.H. Barad V.A. Kushnir E. Lazzaroni Q.i. Wang D.F. Albertini et al. Aging-related premature luteinization of granulosa cells is avoided by early oocyte retrieval 226 3 2015 167 180","DOI":"10.1530\/JOE-15-0246"},{"key":"10.1016\/j.ejogrb.2021.07.035_b0100","doi-asserted-by":"crossref","unstructured":"The Ganirelix Dose-finding Study Group. A double-blind, randomized, dosefinding study to assess the efficacy of the gonadotrophin-releasing hormon antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. Hum Reprod 1998;13:3023-31.","DOI":"10.1093\/humrep\/13.11.3023"},{"key":"10.1016\/j.ejogrb.2021.07.035_b0105","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0015-0282(99)00414-8","article-title":"Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon\/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers","volume":"72","author":"Obery\u00e9","year":"1999","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.ejogrb.2021.07.035_b0110","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1210\/er.2018-00075","article-title":"Ovulation: parallels with inflammatory processes","volume":"40","author":"Duffy","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejogrb.2021.07.035_b0115","doi-asserted-by":"crossref","unstructured":"Choi Y, Wilson K, Hannon PR, Rosewell KL, Br\u00e4nnstrom M, Akin JW, et al. Coordinated regulation among progesterone, prostaglandins, and EGF-like factors in human ovulatory follicles. J Clin Endocrinol Metab 2017;102(6):1971-82.","DOI":"10.1210\/jc.2016-3153"},{"key":"10.1016\/j.ejogrb.2021.07.035_b0120","doi-asserted-by":"crossref","unstructured":"G.M. Yerushalmi S. Markman Y. Yung E. Maman S. Aviel-Ronen R. Orvieto et al. The prostaglandin transporter (PGT) as a potential mediator of ovulation Sci Transl Med 8 338 2016 338ra68 338ra68","DOI":"10.1126\/scitranslmed.aad2709"},{"issue":"4","key":"10.1016\/j.ejogrb.2021.07.035_b0125","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1472-6483(10)62164-5","article-title":"Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles","volume":"6","author":"Ulug","year":"2003","journal-title":"Reproductive BioMedicine Online"},{"issue":"11","key":"10.1016\/j.ejogrb.2021.07.035_b0130","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10815-007-9142-9","article-title":"Cytokines: Important for implantation?","volume":"24","author":"Chaouat","year":"2007","journal-title":"J Assist Reprod Genet"},{"issue":"2","key":"10.1016\/j.ejogrb.2021.07.035_b0135","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/humrep\/dei343","article-title":"Indomethacin effect on implantation rates in oocyte recipients","volume":"21","author":"Bernabeu","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2021.07.035_b0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.prostaglandins.2017.11.001","article-title":"Comprehensive profiling of prostaglandins in human ovarian follicular fluid using mass spectrometry","volume":"134","author":"Pier","year":"2018","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.ejogrb.2021.07.035_b0145","doi-asserted-by":"crossref","unstructured":"The ESHRE Guideline Group on Ovarian Stimulation, Ernesto Bosch, Simone Broer, Georg Griesinger, Michael Grynberg, Peter Humaidan, Estratios Kolibianakis et al. ESHRE guideline: ovarian stimulation for IVF\/ICSI\u2020 (2020). Human Reproduction Open 2020(2):hoaa009.","DOI":"10.1093\/hropen\/hoaa009"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030121152100378X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030121152100378X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:55:00Z","timestamp":1759557300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030121152100378X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":29,"alternative-id":["S030121152100378X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2021.07.035","relation":{},"ISSN":["0301-2115"],"issn-type":[{"type":"print","value":"0301-2115"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of indomethacin on the number of oocytes retrieved and IVF outcomes in patients with poor ovarian response","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2021.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}